Last reviewed · How we verify
NCT04133077: XenoBreast
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
NA trial testing blood samples collection in Breast Cancer Female in 85 participants. Currently enrolling.
31 August 2030
Quick facts
| Lead sponsor | Centre Jean Perrin |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 85 |
| Start date | 19 November 2021 |
| Primary completion | 31 August 2030 |
| Estimated completion | 31 August 2030 |
| Sites | 1 location across France |
Drugs / interventions tested
- blood samples collection — full drug profile →
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
Sponsor
Centre Jean Perrin — full company profile →
Who can join
18 and older, female only, with Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient-derived xenograft models in cancer therapy: technologies and applications.
Liu Y, Wu W, Cai C, Zhang H, et al · · 2023 · cited 290× · PMID 37045827 · DOI 10.1038/s41392-023-01419-2 -
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer.
Veyssière H, Passildas J, Ginzac A, Lusho S, et al · · 2020 · cited 2× · PMID 34249349 · DOI 10.12688/f1000research.26873.3 -
Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.
Jian C, Fu H, Wu W, Zhang N, et al · · 2026 · PMID 41699647 · DOI 10.1186/s12943-026-02594-w -
XENOBREAST Trial: A prospective study of xenografts establishment from surgical specimens of patients with triple negative or luminal b breast cancer
Veyssière H, Passildas J, Ginzac A, Lusho S, et al · · 2021 · DOI 10.12688/f1000research.26873.3
Verify or expand the search:
- PubMed search for NCT04133077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood samples collection
Trials testing the same drug.
- NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting
- NCT05384522 — Analysis of the Prognostic Role of Epigenetic Biomarkers in Relation to the Motor Decline in Parkinson's Disease · unknown
- NCT04002570 — Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients · completed
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other Centre Jean Perrin trials
Trials by the same sponsor.
- NCT07361471 — Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovari · NA · recruiting
- NCT06512558 — Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery · NA · recruiting
- NCT06600802 — Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA- · NA · recruiting
- NCT05433077 — Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment · active not recruiting
- NCT05157594 — hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04133077 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Jean Perrin
- Last refreshed: 19 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04133077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing